Clinical case of mantle cell lymphoma of the prostate
R. N. Trushkin,
E. A. Baryakh,
P. E. Medvedev,
Yu. A. Lagoyskaya,
E. A. Semenova,
D. V. Fettser,
A. A. Chumikov,
T. K. Isaev https://doi.org/10.17650/1726-9776-2024-20-3-130-135
Abstract
The article presents a clinical case of mantle cell lymphoma of the prostate in a 75-year-old man who was hospitalized in the Emergency Urological Department of the City Clinical Hospital No. 52 with gross hematuria through cystostomy tube. During examination the patient was found to have prostatomegaly (prostate volume 992 cm3), prostate-specific antigen level was 2.2 ng/mL. Immunohistochemical examination of prostate tissue after adenectomy indicates prostate damage due to mantle cell lymphoma.
About the Authors
R. N. Trushkin
City Clinical Hospital No. 52, Moscow Healthcare Department
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182
E. A. Baryakh
City Clinical Hospital No. 52, Moscow Healthcare Department;
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University);
Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182,
Build. 2, 8 Trubetskaya St., Moscow 119991,
Build. 1, 2/3 Barrikadnaya St., Moscow 125993
P. E. Medvedev
City Clinical Hospital No. 52, Moscow Healthcare Department
Russian Federation
Russian Federation
Pavel E. Medvedev
3 Pekhotnaya St., Moscow 123182
Yu. A. Lagoyskaya
City Clinical Hospital No. 52, Moscow Healthcare Department
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182
E. A. Semenova
City Clinical Hospital No. 52, Moscow Healthcare Department
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182
D. V. Fettser
City Clinical Hospital No. 52, Moscow Healthcare Department
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182
A. A. Chumikov
City Clinical Hospital No. 52, Moscow Healthcare Department
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182
T. K. Isaev
City Clinical Hospital No. 52, Moscow Healthcare Department
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182
References
1. Teras L.R., DeSantis C.E., Cerhan J.R. et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Canser J Clin 2016;66(6):443–59. DOI: 10.3322/caac.21357
2. Armitage J.O., Longo D.L. Mantle cell lymphoma. N Engl J Med 2022;386(26):2495–506. DOI: 10.1056/NEJMra2202672
3. Campo E., Jaffe E.S., Cook J.R. et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 2022;140(11):1229–53. DOI: 10.1182/blood.2022015851
4. Alaggio R., Amador C., Anagnostopoulos I. et al. The 5th edition of the World Health Organisation Classification of hematolymphoid tumors: Lymphoid Neoplasms. Leukemia 2022;36(7):1720–48. DOI: 10.1038/s41375-022-01620-2
5. Olweny C.L. Cotswolds modification of the Ann Arbor staging system for Hodgkin’s disease. J Clin Oncol 1990;8(9):1598.
6. Hoster E., Dreyling M., Klapper W. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111(2):558–6. DOI: 10.1182/blood-2007-06-095331
7. Vorobyev V.I., Tumyan G.S. Mantle cell lymphoma. Russian clinical guidelines on diagnosis and treatment of malignant lymphoproliferative diseases. Eds.: I.V. Poddubnaya, V.G. Savchenko. 2020. (In Russ.).
8. Doshi K., Chandran A., Li Y. et al. Mantle zone lymphoma with prostate gland enlargement: a case report. Cureus 2022;14(11):e32045. DOI: 10.7759/cureus.32045
9. Dreyling M.M., Doorduijn J.K., Gine E. et al. Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the European MCL Network. Blood 2022;140(Suppl 1):1–3.
10. National Comprehensive Cancer Network. Available at: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf
11. Belkacemi Y., Sio T.T., Colson-Durand L. et al. Primary extranodal lymphoma of the glands. Literature review and options for best practice in 2019. Crit Rev Oncol Hematol 2019;135:8–19. DOI: 10.1016/j.critrevonc.2019.01.005
12. Milburn P.A., Cable C.T., Trevathan S., El Tayeb M.M. Mantle cell lymphoma of the prostate gland treated with holmium laser enucleation. Proc (Bayl Univ Med Cent) 2017;30(3):338–9. DOI: 10.1080/08998280.2017.11929640
13. Karademir B., Kısa E., Özbilen M.H. et al. Unexpected hematologic malignancies after prostatectomy: case report and literature review. Urologia 2021;88(4):382–5. DOI: 10.1177/0391560321993596
14. Kumar P., Rahman K., Hussein N. et al. Primary prostatic nonHodgkin’s lymphoma presenting with features of prostatism. J Cancer Res Ther 2019;15:178–9. DOI: 10.4103/jcrt.JCRT_886_16
Review
For citations:
Trushkin R.N., Baryakh E.A., Medvedev P.E., Lagoyskaya Yu.A., Semenova E.A., Fettser D.V., Chumikov A.A., Isaev T.K. Clinical case of mantle cell lymphoma of the prostate. Cancer Urology. 2024;20(3):130-135. (In Russ.) https://doi.org/10.17650/1726-9776-2024-20-3-130-135
Views:
239
Email this article 